At 8.3% CAGR, North America Poultry Vaccines Market is Projected to be Worth US$ 1,327.26 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the North America poultry vaccines market was valued at US$ 702.04 million in 2023 and is anticipated to reach US$ 1,327.26 million by 2031, registering a CAGR of 8.3% from 2023 to 2031. Advancements in vectored and combination vaccines and growing poultry industry are among the critical factors attributed to drive the North America poultry vaccines market growth.

Vectored vaccines work differently from conventional vaccines and offer several advantages. These advantages include no adverse effects/reactions, overcoming maternal antibody interference, and meeting evolving disease challenges, among others. The "Vaxxitek HVT+IBD+ND" is an example of a vector vaccine manufactured by Boehringer Ingelheim and was launched in the US market in 2019. It is a trivalent vaccine and is effective against three diseases: Marek's disease (MD), Infectious Bursal Disease (IBD), and Newcastle disease (ND). Additionally, in 2020, a second trivalent form, "Vaxxitek HVT+IBD+ILT," received marketing authorization in the US to protect against MD, IBD, and Infectious Laryngotracheitis (ILT). These are all highly infectious and commercially disruptive diseases that affect the poultry industry worldwide, and Vaxxitek proves beneficial in overcoming such diseases in one shot. Other manufacturers except Boehringer Ingelheim producing such bivalent and trivalent vaccines will enhance global demand. Also, major manufacturers plan to procure pentavalent vaccines that will prove beneficial to overcome poultry diseases and help them stand out in the global market.

On the contrary, vaccination failure and improper handling hamper the growth of North America poultry vaccines market.

Based on type, the North America poultry vaccines market is bifurcated into broiler and layer. The broiler segment held 60.6% market share in 2023, amassing US$ 425.17 million. It is projected to garner US$ 824.86 million by 2031 to register 8.6% CAGR during 2023–2031.

In terms of technology, the North America poultry vaccines market is segmented into live attenuated vaccines, inactivated vaccines, and recombinant vaccines. The live attenuated vaccines segment held 52.5% share of North America poultry vaccines market in 2023, amassing US$ 368.90 million. It is projected to garner US$ 706.89 million by 2031 to register 8.5% CAGR during 2023–2031.

By dosage form, the North America poultry vaccines market is segmented into liquid vaccines, freeze-dried vaccines, and dust/powdered form vaccines. The liquid vaccines segment held 57.2% share of North America poultry vaccines market in 2023, amassing US$ 401.71 million. It is projected to garner US$ 783.53 million by 2031 to expand at 8.7% CAGR from 2023 to 2031.

Based on type of disease, the North America poultry vaccines market is categorized into avian influenza, infectious bronchitis, Marek's disease, avian salmonellosis, infectious bursal disease (IBD), Newcastle disease, and others. The avian influenza segment held 30.3% share of North America poultry vaccines market in 2023, amassing US$ 212.50 million. It is predicted to garner US$ 421.93 million by 2031 to expand at 9.0% CAGR between 2023 and 2031.

By route of administration, the North America poultry vaccines market is segmented into drinking water (D/W), intramuscular (I/M), subcutaneous (I/S), and others. The drinking water (D/W) segment held 40.6% share of North America poultry vaccines market in 2023, amassing US$ 285.35 million. It is estimated to garner US$ 562.57 million by 2031 to expand at 8.9% CAGR during 2023–2031.

In terms of end user, the North America poultry vaccines market is categorized into poultry farms & hatchery, veterinary hospitals, and poultry vaccination enters & clinics. The poultry farms & hatchery segment held 52.3% share of North America hearing aids market in 2023, amassing US$ 367.06 million. It is projected to garner US$ 720.29 million by 2031 to expand at 8.8% CAGR from 2023 to 2031.

Based on country, the North America poultry vaccines market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 86.9% share of North America poultry vaccines market in 2023. It was assessed at US$ 609.93 million in 2023 and is likely to hit US$ 1,175.43 million by 2031, registering a CAGR of 8.5% during 2023–2031.

Key players operating in the North America poultry vaccines market are Boehringer Ingelheim International GmbH, Zoetis Inc, Phibro Animal Health Corp, Dechra Pharmaceuticals PLC, Elanco Animal Health Inc, Merck KGaA, Ceva, and Vaccinova AB, among others.

• In January 2020, Boehringer Ingelheim has launched VAXXITEK HVT+IBD+ND. The vaccines provides a strong immune foundation and optimized protection against Marek's disease, Infectious Bursal Disease (classic and variant types) and Newcastle Disease.
• In June 2019, Zoetis has reintroduced the vaccine Poulvac Coryza ABC IC3 to help U.S. poultry producers combat outbreaks of avian coryza, an acute respiratory infection, according to an announcement.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com